Reported Earnings • Aug 31
First half 2025 earnings released: HK$0.078 loss per share (vs HK$0.89 loss in 1H 2024) First half 2025 results: HK$0.078 loss per share (improved from HK$0.89 loss in 1H 2024). Revenue: HK$421.2m (up 2.7% from 1H 2024). Net loss: HK$38.7m (loss narrowed 91% from 1H 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Ankündigung • Aug 18
Lippo Limited to Report First Half, 2025 Results on Aug 28, 2025 Lippo Limited announced that they will report first half, 2025 results on Aug 28, 2025 New Risk • May 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (HK$315.6m market cap, or US$40.3m). Ankündigung • May 22
Lippo Limited, Annual General Meeting, Jun 23, 2025 Lippo Limited, Annual General Meeting, Jun 23, 2025, at 11:45 China Standard Time. Location: concord room, 8th floor, renaissance harbour view hotel hong kong, 1 harbour road., wanchai Hong Kong Reported Earnings • Mar 30
Full year 2024 earnings released: HK$2.86 loss per share (vs HK$0.072 loss in FY 2023) Full year 2024 results: HK$2.86 loss per share (further deteriorated from HK$0.072 loss in FY 2023). Revenue: HK$848.8m (up 4.3% from FY 2023). Net loss: HK$1.41b (loss widened HK$1.38b from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance. Ankündigung • Mar 18
Lippo Limited to Report Fiscal Year 2024 Results on Mar 28, 2025 Lippo Limited announced that they will report fiscal year 2024 results on Mar 28, 2025 New Risk • Jan 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (HK$577.0m market cap, or US$74.3m). Reported Earnings • Sep 30
First half 2024 earnings released: HK$0.89 loss per share (vs HK$0.005 profit in 1H 2023) First half 2024 results: HK$0.89 loss per share (down from HK$0.005 profit in 1H 2023). Revenue: HK$410.0m (up 6.0% from 1H 2023). Net loss: HK$436.9m (down HK$439.7m from profit in 1H 2023). Reported Earnings • Aug 30
First half 2024 earnings released: HK$0.89 loss per share (vs HK$0.005 profit in 1H 2023) First half 2024 results: HK$0.89 loss per share (down from HK$0.005 profit in 1H 2023). Revenue: HK$410.0m (up 6.0% from 1H 2023). Net loss: HK$436.9m (down HK$439.7m from profit in 1H 2023). Ankündigung • Aug 15
Lippo Limited to Report Q2, 2024 Results on Aug 27, 2024 Lippo Limited announced that they will report Q2, 2024 results on Aug 27, 2024 Ankündigung • Jun 09
Lippo Limited Announces Chief Executive Officer Changes, Effective from 7 June 2024 The Board of Directors of Lippo Limited announce that Mr. John Luen Wai Lee will be re-designated from the Managing Director and Chief Executive Officer to the Deputy Chairman of the Company with effect from 7 June 2024. He remains as an executive Director of the Company. The company announce that Mr. Kwok Fai Lee will be appointed as Chief Executive Officer of the Company with effect from 7 June 2024. Mr. Kwok Fai Lee (alias: Davy) ("Mr. Lee"), aged 65, is a fellow member of The Chartered Governance Institute and The Hong Kong Chartered Governance Institute. He will also be appointed as an executive director and the Chief Executive Officer of each of LCR and HKC with effect from 7 June 2024. Mr. Lee is an authorised representative of the Company and an alternate to authorised representative of LCR and HKC. In addition, he holds directorships in certain subsidiaries of the Company and the Company's controlling shareholders. Mr. Lee had not held any directorship in listed public companies for the last three years. Mr. Lee has over 30 years' experience in treasury investments, corporate administration and company secretarial field. Mr. Lee holds a Bachelor of Arts in Chinese Humanities (First Class Honours) from The Open University of Hong Kong (now known as Hong Kong Metropolitan University), a Master of Science in Investment Management from The Hong Kong University of Science and Technology and a Doctor of Business and Administration from The Hong Kong Polytechnic University. Mr. Lee has served the Lippo group of companies for over 40 years. Mr. Lee has been the Secretary of the Company since 22 April 1991 as well as the Secretary of Lippo Capital Limited, Lippo Capital Holdings Company Limited and Lippo Capital Group Limited which have discloseable interests in the Company under the provisions of the SFO. He is also the Secretary of certain subsidiaries of the Company's controlling shareholders and the Company. Ankündigung • Jun 08
Lippo Limited Announces Executive and Company Secretary Changes The Board of Directors of Lippo Limited announce that Mr. John Luen Wai Lee will be re-designated from the Managing Director and Chief Executive Officer to the Deputy Chairman of the Company with effect from 7 June 2024. He remains as an executive Director of the Company. The biographical details of Mr. John Luen Wai Lee are set out below. Mr. John Luen Wai Lee, BBS, JP, aged 75, was appointed a Director of the Company on 21 March 1991. Mr. Lee is the Managing Director and Chief Executive Officer of the Company. Mr. Lee is also an executive director and the Chief Executive Officer of Lippo China Resources Limited ("LCR", a subsidiary of the Company) and Hongkong Chinese Limited ("HKC", a subsidiary of the Company), as well as an independent non-executive director of New World Development Company Limited and UMP Healthcare Holdings Limited, all are listed public companies in Hong Kong. With effect from 7 June 2024, Mr. Lee will be re-designated from the Chief Executive Officer to the Deputy Chairman of LCR and HKC. Mr. Lee is an authorised representative of the Company, LCR and HKC. In addition, he holds directorships in certain subsidiaries of the Company. Save as disclosed herein, Mr. Lee had not held any directorship in other listed public companies for the last three years. Mr. Lee is a Fellow of The Institute of Chartered Accountants in England and Wales, the Association of Chartered Certified Accountants and the Hong Kong Institute of Certified Public Accountants. He was a partner of Price Waterhouse (now known as PricewaterhouseCoopers) in Hong Kong and has extensive experience in corporate finance and capital markets. Mr. Lee is an Honorary Fellow of the City University of Hong Kong, a Justice of Peace in Hong Kong and an awardee of the Bronze Bauhinia Star by the Government of the Hong Kong Special Administrative Region. Mr. Lee is active in public service. Over the years, he served as a member or chairman of different government boards and committees in Hong Kong, including a member of the Hong Kong Hospital Authority and the Chairman of the Hospital Governing Committee of the Queen Elizabeth Hospital and Hong Kong Children's Hospital. The Board is also pleased to announce that Mr. Kwok Fai Lee will be appointed as an executive Director and the Chief Executive Officer of the Company with effect from 7 June 2024. The biographical details of Mr. Kwok Fai Lee are set out below. Mr. Kwok Fai Lee aged 65, is a fellow member of The Chartered Governance Institute and The Hong Kong Chartered Governance Institute. He will also be appointed as an executive director and the Chief Executive Officer of each of LCR and HKC with effect from 7 June 2024. Mr. Lee is an authorised representative of the Company and an alternate to authorised representative of LCR and HKC. In addition, he holds directorships in certain subsidiaries of the Company and the Company's controlling shareholders. Mr. Lee had not held any directorship in listed public companies for the last three years. Mr. Lee has over 30 years' experience in treasury investments, corporate administration and company secretarial field. Mr. Lee holds a Bachelor of Arts in Chinese Humanities (First Class Honours) from The Open University of Hong Kong (now known as Hong Kong Metropolitan University), a Master of Science in Investment Management from The Hong Kong University of Science and Technology and a Doctor of Business and Administration from The Hong Kong Polytechnic University. Mr. Lee has served the Lippo group of companies for over 40 years. Mr. Lee has been the Secretary of the Company since 22 April 1991 as well as the Secretary of Lippo Capital Limited, Lippo Capital Holdings Company Limited and Lippo Capital Group Limited which have discloseable interests in the Company under the provisions of the SFO. He is also the Secretary of certain subsidiaries of the Company's controlling shareholders and the Company. The Board announces that following the appointment of Mr. Kwok Fai Lee as an executive Director and the Chief Executive Officer of the Company, he will resign as the Company Secretary of the Company with effect from 7 June 2024. The Board also announce that Ms. Millie Yuen Fun Luk will be appointed as the Company Secretary of the Company with effect from 7 June 2024. Ms. Luk has over 30 years of experience in the legal and company secretarial fields with various listed companies and is currently the Company Secretary of LCR and HKC. She is a Chartered Secretary, a Chartered Governance Professional and a fellow member of The Chartered Governance Institute and The Hong Kong Chartered Governance Institute. Ankündigung • Mar 28
Lippo Limited, Annual General Meeting, Jun 06, 2024 Lippo Limited, Annual General Meeting, Jun 06, 2024. Reported Earnings • Mar 28
Full year 2023 earnings released: HK$0.07 loss per share (vs HK$0.25 profit in FY 2022) Full year 2023 results: HK$0.07 loss per share (down from HK$0.25 profit in FY 2022). Revenue: HK$813.5m (up 20% from FY 2022). Net loss: HK$35.4m (down 128% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Ankündigung • Mar 16
Lippo Limited to Report Fiscal Year 2023 Final Results on Mar 27, 2024 Lippo Limited announced that they will report fiscal year 2023 final results on Mar 27, 2024 Reported Earnings • Oct 01
First half 2023 earnings released: EPS: HK$0.005 (vs HK$0.21 in 1H 2022) First half 2023 results: EPS: HK$0.005 (down from HK$0.21 in 1H 2022). Revenue: HK$386.9m (up 23% from 1H 2022). Net income: HK$2.71m (down 97% from 1H 2022). Profit margin: 0.7% (down from 34% in 1H 2022). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 01
First half 2023 earnings released: EPS: HK$0.005 (vs HK$0.21 in 1H 2022) First half 2023 results: EPS: HK$0.005 (down from HK$0.21 in 1H 2022). Revenue: HK$386.9m (up 23% from 1H 2022). Net income: HK$2.71m (down 97% from 1H 2022). Profit margin: 0.7% (down from 34% in 1H 2022). Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. New Risk • Aug 31
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 58% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.0% net profit margin). Market cap is less than US$100m (HK$720.0m market cap, or US$91.8m). Ankündigung • Aug 23
Lippo Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023 Lippo Limited provided earnings guidance for the six months ended 30 June 2023. The company estimated that it may record a net fair value gain on financial instruments at fair value through profit or loss of approximately HKD 29 million for the six months ended 30 June 2023 (the "Period"), as compared to a fair value loss of HKD 25 million for the six months ended 30 June 2022 (the "Last Period"). Based on information currently available to the Company, the Board estimates that the Group may record a consolidated profit attributable to shareholders of approximately HKD 3 million for the Period, as compared to a consolidated profit of HKD 105 million for the Last Period. The change was mainly attributable to decrease in share of profit of joint ventures of the Group for the Period, but offset by the aforesaid net fair value change on financial instruments of the Group and the improvement in the performance of the Group's food businesses. Ankündigung • Aug 19
Lippo Limited to Report First Half, 2023 Results on Aug 30, 2023 Lippo Limited announced that they will report first half, 2023 results on Aug 30, 2023 Reported Earnings • Mar 31
Full year 2022 earnings released: EPS: HK$0.25 (vs HK$1.01 in FY 2021) Full year 2022 results: EPS: HK$0.25 (down from HK$1.01 in FY 2021). Revenue: HK$677.8m (down 6.9% from FY 2021). Net income: HK$125.3m (down 75% from FY 2021). Profit margin: 19% (down from 69% in FY 2021). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Board Change • Jan 03
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. No experienced directors. 7 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Min Yen Goh was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 8 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non Executive Director Victor Yung was the last independent director to join the board, commencing their role in 2004. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 01
First half 2022 earnings released First half 2022 results: EPS: HK$0.21. Net income: HK$105.5m (up HK$105.5m from 1H 2021). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Reported Earnings • Sep 01
First half 2022 earnings released: EPS: HK$0.21 (vs HK$0.24 in 1H 2021) First half 2022 results: EPS: HK$0.21 (down from HK$0.24 in 1H 2021). Revenue: HK$314.9m (up 74% from 1H 2021). Net income: HK$105.5m (down 11% from 1H 2021). Profit margin: 34% (down from 66% in 1H 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Jun 06
Upcoming dividend of HK$0.04 per share Eligible shareholders must have bought the stock before 13 June 2022. Payment date: 29 June 2022. Payout ratio is a comfortable 3.9% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of Hong Kong dividend payers (7.7%). Lower than average of industry peers (2.2%). Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 8 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non Executive Director Victor Yung was the last independent director to join the board, commencing their role in 2004. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Apr 01
Full year 2021 earnings released: EPS: HK$1.01 (vs HK$2.19 loss in FY 2020) Full year 2021 results: EPS: HK$1.01 (up from HK$2.19 loss in FY 2020). Revenue: HK$728.2m (down 4.7% from FY 2020). Net income: HK$500.1m (up HK$1.58b from FY 2020). Profit margin: 69% (up from net loss in FY 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Upcoming Dividend • Jun 04
Upcoming dividend of HK$0.03 per share Eligible shareholders must have bought the stock before 10 June 2021. Payment date: 30 June 2021. Trailing yield: 2.9%. Lower than top quartile of Hong Kong dividend payers (5.9%). Higher than average of industry peers (1.9%). Reported Earnings • Dec 31
First half 2021 earnings released: HK$1.30 loss per share The company reported a poor first half result with weaker earnings, revenues and control over expenses. First half 2021 results: Revenue: HK$387.4m (down 27% from 1H 2020). Net loss: HK$643.2m (down HK$735.3m from profit in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 65% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Dec 30
New 90-day high: HK$2.48 The company is up 14% from its price of HK$2.18 on 30 September 2020. The Hong Kong market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is down 13% over the same period. Reported Earnings • Nov 29
First half 2021 earnings released: HK$1.30 loss per share The company reported a poor first half result with weaker earnings, revenues and control over expenses. First half 2021 results: Revenue: HK$387.4m (down 27% from 1H 2020). Net loss: HK$643.2m (down HK$731.9m from profit in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 65% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Nov 04
New 90-day low: HK$2.04 The company is down 14% from its price of HK$2.38 on 06 August 2020. The Hong Kong market is flat over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 22% over the same period. Is New 90 Day High Low • Sep 28
New 90-day low: HK$2.06 The company is down 12% from its price of HK$2.35 on 30 June 2020. The Hong Kong market is flat over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 29% over the same period. 
